1M6MYTD1Y5YMAX
Loading quotes...
Forecast
The analysts' average price target is €7.67 (+115.45%). The median is €4.31 (+21.07%).
| Buy |
10 |
| Hold |
6 |
| Sell |
0 |
News Go to news feed
There is currently no news available for this company. We are working on adding more providers to change this.
Financials
| (EUR) | September 2025 | |
|---|---|---|
| Revenue | 0 | - |
| Gross profit | -396.24K | - |
| Net profit | -40.61M | - |
| EBITDA | -40.21M | - |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €83M |
Number of shares | 22.08M |
52-week high/low | €5.23 - €1.53 |
| Dividends | No |
Beta | 0.87 |
P/E ratio | -0.66 |
PEG ratio | 0.01 |
P/B ratio | -1.84 |
P/S ratio | 0.00 |
Company profile
| Name | Adverum Biotechnologies Aktie |
| CEO | Laurent Fischer |
| Employees | 155 |
Discover assets
Shareholders of Adverum Biotechnologies Aktie also invest in the following assets
